Ludvigsson J - Search Results

1

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J; Protégé Trial Investigators. Hagopian W, et al. Among authors: ludvigsson j. Diabetes. 2013 Nov;62(11):3901-8. doi: 10.2337/db13-0236. Epub 2013 Jun 25. Diabetes. 2013. PMID: 23801579 Free PMC article. Clinical Trial.

2

Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years.

Nordwall M, Ludvigsson J. Nordwall M, et al. Among authors: ludvigsson j. Diabetes Metab Res Rev. 2008 Sep;24(6):472-9. doi: 10.1002/dmrr.871. Diabetes Metab Res Rev. 2008. PMID: 18613248

3

Health-related quality of life in intensively treated young patients with type 1 diabetes.

Hanberger L, Ludvigsson J, Nordfeldt S. Hanberger L, et al. Among authors: ludvigsson j. Pediatr Diabetes. 2009 Sep;10(6):374-81. doi: 10.1111/j.1399-5448.2008.00496.x. Epub 2009 Jan 21. Pediatr Diabetes. 2009. PMID: 19207230

4

Therapy with GAD in diabetes.

Ludvigsson J. Ludvigsson J. Diabetes Metab Res Rev. 2009 May;25(4):307-15. doi: 10.1002/dmrr.941. Diabetes Metab Res Rev. 2009. PMID: 19267332 Review.

5

The role of immunomodulation therapy in autoimmune diabetes.

Ludvigsson J; Linköping Diabetes Immune Intervention Study Group. Ludvigsson J, et al. J Diabetes Sci Technol. 2009 Mar 1;3(2):320-30. doi: 10.1177/193229680900300213. J Diabetes Sci Technol. 2009. PMID: 20144363 Free PMC article. Review.

6

GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.

Skoglund C, Chéramy M, Casas R, Ludvigsson J, Hampe CS. Skoglund C, et al. Among authors: ludvigsson j. Pediatr Diabetes. 2012 May;13(3):244-50. doi: 10.1111/j.1399-5448.2011.00802.x. Epub 2011 Aug 16. Pediatr Diabetes. 2012. PMID: 21848927 Free PMC article. Clinical Trial.

7

A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes.

Carlsson A, Forsander G, Ludvigsson J, Larsen S, Ortqvist E; Swedish PREDICTIVE-Youth Study Group. Carlsson A, et al. Among authors: ludvigsson j. Pediatr Diabetes. 2013 Aug;14(5):358-65. doi: 10.1111/pedi.12019. Epub 2013 Mar 1. Pediatr Diabetes. 2013. PMID: 23448369 Free PMC article.

8

Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents.

Ludvigsson J, Carlsson A, Deli A, Forsander G, Ivarsson SA, Kockum I, Lindblad B, Marcus C, Lernmark Å, Samuelsson U. Ludvigsson J, et al. Diabetes Res Clin Pract. 2013 May;100(2):203-9. doi: 10.1016/j.diabres.2013.03.003. Epub 2013 Mar 22. Diabetes Res Clin Pract. 2013. PMID: 23529064

9

GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.

Ludvigsson J, Chéramy M, Axelsson S, Pihl M, Akerman L, Casas R; Clinical GAD-Study Group in Sweden. Ludvigsson J, et al. Diabetes Metab Res Rev. 2014 Jul;30(5):405-14. doi: 10.1002/dmrr.2503. Diabetes Metab Res Rev. 2014. PMID: 24302596 Clinical Trial.

10

Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden).

Nordwall M, Abrahamsson M, Dhir M, Fredrikson M, Ludvigsson J, Arnqvist HJ. Nordwall M, et al. Among authors: ludvigsson j. Diabetes Care. 2015 Feb;38(2):308-15. doi: 10.2337/dc14-1203. Epub 2014 Dec 15. Diabetes Care. 2015. PMID: 25510400

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,295 results

Search Page

Filters